What's Happening?
Privia Health, in collaboration with Amalgam Rx and Exact Sciences Corp., has achieved an 84% colorectal cancer screening rate through a coordinated, EHR-enabled patient outreach program. The initiative, launched in 2023 and expanded nationally in 2024,
utilized Amalgam's clinical decision support and Exact Sciences' Cologuard test to increase screening rates among eligible patients aged 45 and older. The program engaged over 100,000 patients, processed 23,000 screening orders, and identified more than 550 patients requiring follow-up, demonstrating the effectiveness of data-driven approaches in closing screening gaps.
Why It's Important?
This program highlights the potential of technology-driven healthcare solutions to improve cancer screening rates and patient outcomes. By integrating clinical decision support and patient engagement within EHR workflows, the initiative reduced administrative burdens and increased access to noninvasive screening options. The success of this program supports value-based care objectives and positions health systems for future digital quality measurement requirements, ultimately contributing to better healthcare delivery and reduced cancer mortality.
What's Next?
Privia Health plans to apply insights from this colorectal cancer screening program to other preventive care initiatives, focusing on scalable, data-driven approaches to patient engagement and quality improvement. The collaboration aims to continue enhancing healthcare delivery by leveraging technology to streamline processes and improve patient outcomes across various health conditions.
